Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma

Kevin R. Kelly, MD, PhD
Published: Monday, Feb 20, 2017



Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory myeloma.

There is an interesting study of BT062, explains Kelly. It is an antibody-drug conjugate with the chemotherapy attached to CD138, which is a marker in myeloma cells. This combination is with lenalidomide and, so far, relapsed/refractory patients with multiple myeloma patients are experiencing active responses.

We are going to continue to follow these patients for progression, states Kelly. We have not yet reached a median progression free survival, but prolonged durable responses to the combination treatment have been seen.
 


Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory myeloma.

There is an interesting study of BT062, explains Kelly. It is an antibody-drug conjugate with the chemotherapy attached to CD138, which is a marker in myeloma cells. This combination is with lenalidomide and, so far, relapsed/refractory patients with multiple myeloma patients are experiencing active responses.

We are going to continue to follow these patients for progression, states Kelly. We have not yet reached a median progression free survival, but prolonged durable responses to the combination treatment have been seen.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x